2,4-pyrimidinediamine compounds and their uses
The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.
1. A method, comprising administering to a subject a compound according to Formula (I)
or a salt thereof, wherein:
one of R 2 and R 4 is a phenyl monosubstituted with (C1-C6) alkyl, —OR a , —O—C(O)OR a , —O—(CH 2 ) m —C(O)OR a , —C(O)OR a , —O—(CH 2 ) m —NR c R c , —O—C(O)NR c R c , —O—(CH 2 ) m —C(O)NR c R c , —O—C(NH)NR c R c , —O—(CH 2 ) m —C(NH)NR c R c , —NH—(CH 2 ) m —NR c R c or —[NHC(O)]R d ;
the other of R 2 and R 4 is a phenyl monosubstituted or disubstituted with R 8 ;
R 2 and R 4 are different;
R 5 is fluoro, —CN, or (C1-C3) haloalkyl;
each R 8 is independently R a , R b , or R a substituted with one R a or R b ;
each R a is (C1-C6) alkyl, or 3-8 membered cycloheteroalkyl;
each R b is —O a , —OCF 3 , —NR c R c , halogen, —CF 3 , —CN, —SO 2 NR c R c , —C(O)R a , —C(O)OR a , —C(O)NR c R c , or —C(NH)NR c R c ;
each R c is independently R a or, alternatively, two R c are taken together with the nitrogen atom to which they are bonded to form a 5 or 6-membered cycloheteroalkyl or heteroaryl which may optionally include one or more of the same or different additional heteroatoms and which may optionally be substituted with one or more of the same or different R a or suitable R b groups;
each R d is independently R a ; and
each m is independently an integer from 1 to 2.
2. A method for treating a disease associated with tissue inflammation comprising administering to a subject an effective amount of a compound having Formula (I)
or a salt thereof, wherein:
one of R 2 and R 4 is a phenyl monosubstituted with (C1-C10) alkyl, —OR a optionally substituted with one R group, —O—C(O)OR a , —O—(CH 2 ) m —C(O)OR a , —C(O)OR a , —O—(CH 2 ) m —NR c R c , —O—C(O)NR c R c , —O—(CH 2 ) m —C(O)NR c R c , —O—C(NH)NR c R c , —O—(CH 2 ) m —C(NH)NR c R c ; —NH—(CH 2 ) m —NR c R c or —[NHC(O)] n R d ;
the other of R 2 and R 4 is a phenyl monosubstituted or disubstituted with R 8 ;
R 2 and R 4 are different;
R 5 is —NR c R c , fluoro, —CN, or (C1-C6) alkyl optionally substituted with one or more of the same or different R 8 groups;
each R 8 is independently R a or R b ;
each R a is H or (C1-C6) alkyl;
each R b is —O CF 3 , —NR c R c , halogen, —CF 3 , —CN, —NO 2 , —N 3 , —SO 2 NR c R c , —C(O)R a , —C(O)OR a , —C(O)NR c R c , —C(NH)NR c R c , —C(NR a )NR c R c , —C(NOH)R a , —C(NOH)NR c R c ;
each R c is independently R a or, alternatively, two R c are taken together with the nitrogen atom to which they are bonded to form a 5 to 8-membered cycloheteroalkyl or heteroaryl which may optionally include one or more of the same or different additional heteroatoms and which is optionally substituted with one or more of the same or different R a or suitable R b groups;
each R d is independently R a ;
each m is independently an integer from 1 to 2; and
each n is independently an integer from 0 to 3.